Moderna Inc (NASDAQ: MRNA) kicked off on Friday, up 0.43% from the previous trading day, before settling in for the closing price of $42.00. Over the past 52 weeks, MRNA has traded in a range of $35.80-$170.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 841.45% over the past five years. While this was happening, its average annual earnings per share was recorded 24.34%. With a float of $343.19 million, this company’s outstanding shares have now reached $385.00 million.
Let’s look at the performance matrix of the company that is accounted for 5600 employees. In terms of profitability, gross margin is 65.9%, operating margin of -53.05%, and the pretax margin is -46.36%.
Moderna Inc (MRNA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Moderna Inc is 10.82%, while institutional ownership is 67.51%. The most recent insider transaction that took place on Dec 09 ’24, was worth 23,637. In this transaction Chief Legal Officer of this company sold 529 shares at a rate of $44.68, taking the stock ownership to the 20,446 shares. Before that another transaction happened on Dec 09 ’24, when Company’s Officer proposed sale 529 for $44.68, making the entire transaction worth $23,637.
Moderna Inc (MRNA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 24.34% per share during the next fiscal year.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Take a look at Moderna Inc’s (MRNA) current performance indicators. Last quarter, stock had a quick ratio of 4.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.82, a number that is poised to hit -2.78 in the next quarter and is forecasted to reach -8.94 in one year’s time.
Technical Analysis of Moderna Inc (MRNA)
Moderna Inc (NASDAQ: MRNA) saw its 5-day average volume 5.76 million, a positive change from its year-to-date volume of 5.43 million. As of the previous 9 days, the stock’s Stochastic %D was 83.19%. Additionally, its Average True Range was 2.26.
During the past 100 days, Moderna Inc’s (MRNA) raw stochastic average was set at 11.35%, which indicates a significant decrease from 68.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.74% in the past 14 days, which was lower than the 55.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $44.30, while its 200-day Moving Average is $88.70. Nevertheless, the first resistance level for the watch stands at $42.84 in the near term. At $43.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $44.38. If the price goes on to break the first support level at $41.30, it is likely to go to the next support level at $40.42. The third support level lies at $39.76 if the price breaches the second support level.
Moderna Inc (NASDAQ: MRNA) Key Stats
The company with the Market Capitalisation of 16.30 billion has total of 384,818K Shares Outstanding. Its annual sales at the moment are 6,848 M in contrast with the sum of -4,714 M annual income. Company’s last quarter sales were recorded 1,862 M and last quarter income was 13,000 K.
